CDC Updates Guidance on Infants With Congenital Zika

Share this content:
CDC Updates Guidance on Infants With Congenital Zika
CDC Updates Guidance on Infants With Congenital Zika

MONDAY, Aug. 22, 2016 (HealthDay News) -- The U.S. Centers for Disease Control and Prevention has released updated interim clinical guidance for health care providers caring for infants born to mothers with possible Zika infection during pregnancy.

Recommendations for the initial evaluation and testing of infants born to mothers with possible Zika infection are based on evidence that has become available since the previous guidance, issued in February. The updated guidance includes recommendations for management, referral to services, and follow-up of infants with laboratory evidence of congenital Zika virus infection.

The updated guidelines do not include dengue testing and recommend against testing cord blood specimens, but do provide information on interpretation of infant laboratory testing results. Even if the prenatal ultrasound was normal, the updated guidance recommends a cranial ultrasound. Additional recommendations are provided in the updated guidance for outpatient management of infants through the first year of life. The importance of establishing a medical home and providing support for families affected by Zika is emphasized. In addition, the guidance includes repeat eye and hearing assessments and a new recommendation for endocrine evaluation.

"CDC recommends coordinated care through a multidisciplinary team and established medical home," the authors write. "As a critical component of patient care and early identification of any delays, families should be empowered to be active participants in their child's monitoring and care."

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »